Immunogenic compositions for the prevention and treatment of meningococcal disease
View Patent ↗The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
1. An isolated polypeptide comprising
the amino acid sequence set forth in any of the even numbered sequences of SEQ ID NOS:2-12.
2. The polypeptide of claim 1 , wherein the polypeptide is encoded by the nucleic acid sequence of any one of the odd numbered sequences of SEQ ID NOS: 1-11.
3. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence of any of the even numbered sequences of SEQ ID NOS: 2-6.
4. The polypeptide of claim 3 , wherein the polypeptide is encoded by the nucleic acid sequence of any one of the odd numbered sequences of SEQ ID NOS: 1-5.
5. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence of any of the even numbered sequences of SEQ ID NOS:8-12.
6. The polypeptide of claim 5 , wherein the polypeptide is encoded by the nucleic acid sequence of any one of the odd numbered sequences of SEQ ID NOS: 7-11.
7. The polypeptide of claim 1 , wherein the polypeptide has a molecular weight of 26,000 to 30,000 Daltons as measured by mass spectroscopy.
8. The polypeptide of claim 1 , wherein the polypeptide has a molecular weight of 28-35 kDa as measured on a 10%-20% SDS polyacrylamide gel.
9. The polypeptide of claim 1 , wherein the polypeptide is non-lipidated.
10. The polypeptide of claim 1 , wherein the polypeptide is a recombinant protein.
11. A composition comprising the polypeptide of claim 1 .
12. The composition of claim 11 , wherein said composition additionally comprises a carrier.
13. The composition of claim 11 , wherein said composition additionally comprises an adjuvant.
14. The composition of claim 13 , wherein said adjuvant comprises a liquid.
15. The composition of claim 11 , wherein said composition additionally comprises a polysaccharide.
16. An isolated polypeptide prepared by a process comprising isolating and purifying from Neisseria meningitidis or recombinantly preparing any of:
(a) a polypeptide comprising the amino acid sequence of any of even numbered SEQ ID NOS: 2-12 or
(b) a polypeptide encoded by a polynucleotide comprising the nucleic acid sequence of any of odd numbered SEQ ID NOS: 1-11.
17. A method of inducing an immune response against Neisseria meningitidis in a mammal comprising administering to the mammal an immunologically effective amount of the composition of claim 11 .
18. The method of claim 17 , wherein said composition is administered parenterally.
19. The method of claim 17 , wherein said composition is administered mucosally.
20. The composition of claim 11 , wherein the composition additionally comprises an additional peptide, polypeptide or protein.
21. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 12.
22. The polypeptide of claim 21 , wherein the polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 12.
23. The polypeptide of claim 21 , wherein the polypeptide is non-lipidated.
24. An immunogenic composition comprising an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO: 12.
25. The composition of claim 14 , wherein the polypeptide is non-lipidated.